Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Stopped early · Not applicable

Conditions studied: Non Small Cell Lung Cancer

In brief

The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.

Key facts

Study ID

NCT05812274

Run by

Columbia University

People needed

30

Starts

2023-05-31

Expected to finish

2025-10-24

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age≥ 18 years
• Confirmed NSCLC diagnosis
• Prescribed treatment with immune-checkpoint inhibitor, including in combination with chemotherapy
• Ability to understand and the willingness to sign a written informed consent document
• Self-identification as a member of an ethnic minority or underserved population.

You may not qualify if…

• An individual with presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study.
• Patients enrolled in other interventional clinical trials at the time of screening will be excluded.

Where it is running

• Montefiore Health Center — New York, New York, United States
• Mount Sinai School of Medicine — New York, New York, United States
• NYU Medical Center — New York, New York, United States
• Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.